Skip to main content
Premium Trial:

Request an Annual Quote

PredictImmune, Addenbrooke's Hospital Sign Agreement to Provide IBD Diagnostic in UK, Ireland

NEW YORK (GenomeWeb) – PredictImmune announced today that it has entered a commercial agreement with Addenbrooke's Hospital — part of Cambridge University Hospitals National Health Service Foundation Trust — to provide the company's PredictSure IBD prognostic assay to clinicians and gastroenterologists in the UK and Ireland.

As part of the agreement, the hospital's East Midlands and East of England Genomic Laboratory hub will manage and facilitate fulfillment of PredictSure IBD orders, in addition to receiving and processing all samples.

PredictImmune's CE-IVD PredictSure platform integrates a blood-based biomarker assay and a proprietary algorithm to identify biomarkers linked to irritable bowel disease (IBD), including Crohn's disease and ulcerative colitis.

PredictImmune said that the agreement will help both clinicians and patients understand the likely course of disease and makes available more treatment choices from initial diagnosis.

"Partnering with Addenbrooke's to make PredictSure available across the UK and Ireland feels very appropriate, given the long-term nature of our collaboration to date," PredictImmune CEO Paul Kinnon said in a statement. "We are excited to see PredictSure IBD become available to UK and Irish patients, particularly because we understand the life-changing benefits that early and accurate prediction of the likely course of their IBD diseases can have on their quality of life."

Financial details of the agreement were not disclosed.

PredictImmune previously announced in March the entry of PredictSure IBD into NICE's Diagnostic Assessment Programme, which evaluates new diagnostic technologies for the UK's NHS.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.